Lumos Pharma Analyst Ratings
Lumos Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/06/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 08/22/2023 | 220.51% | Cantor Fitzgerald | → $10 | Reiterates | Overweight → Overweight |
| 08/15/2023 | 220.51% | Cantor Fitzgerald | $14 → $10 | Maintains | Overweight |
| 08/10/2023 | 444.87% | Oppenheimer | $18 → $17 | Maintains | Outperform |
| 08/10/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 07/24/2023 | 348.72% | Cantor Fitzgerald | → $14 | Reiterates | Overweight → Overweight |
| 06/22/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 05/04/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | → Buy |
| 03/06/2023 | 797.44% | HC Wainwright & Co. | → $28 | Reiterates | → Buy |
| 12/08/2022 | 124.36% | Jefferies | $17 → $7 | Downgrades | Buy → Hold |
| 11/15/2022 | 124.36% | Jefferies | → $7 | Downgrades | Buy → Hold |
| 07/20/2022 | 541.03% | Oppenheimer | → $20 | Initiates Coverage On | → Outperform |
| 11/04/2021 | 797.44% | HC Wainwright & Co. | $27 → $28 | Maintains | Buy |
| 07/21/2021 | 765.38% | HC Wainwright & Co. | $34 → $27 | Maintains | Buy |
| 03/11/2021 | 669.23% | Stifel | $4 → $24 | Upgrades | Hold → Buy |
| 12/03/2020 | 925.64% | Cantor Fitzgerald | → $32 | Initiates Coverage On | → Overweight |
| 11/23/2020 | 989.74% | HC Wainwright & Co. | $33 → $34 | Maintains | Buy |
| 08/26/2020 | 733.33% | Piper Sandler | → $26 | Initiates Coverage On | → Overweight |
| 08/04/2020 | 957.69% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
| 04/16/2020 | 284.62% | Jefferies | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/06/2023 | 797.44% | HC Wainwright公司 | →$28 | 重申 | 購買→購買 |
| 2023年08月22日 | 220.51% | 康託·菲茨傑拉德 | →$10 | 重申 | 超重→超重 |
| 2023年08月15日 | 220.51% | 康託·菲茨傑拉德 | $14→$10 | 維護 | 超重 |
| 2023年08月10日 | 444.87% | 奧本海默 | $18→$17 | 維護 | 跑贏大盤 |
| 2023年08月10日 | 797.44% | HC Wainwright公司 | →$28 | 重申 | 購買→購買 |
| 07/24/2023 | 348.72% | 康託·菲茨傑拉德 | →$14 | 重申 | 超重→超重 |
| 2023/06/22 | 797.44% | HC Wainwright公司 | →$28 | 重申 | 購買→購買 |
| 05/04/2023 | 797.44% | HC Wainwright公司 | →$28 | 重申 | →購買 |
| 03/06/2023 | 797.44% | HC Wainwright公司 | →$28 | 重申 | →購買 |
| 12/08/2022 | 124.36% | 傑富瑞 | $17→$7 | 評級下調 | 購買→Hold |
| 2022年11月15日 | 124.36% | 傑富瑞 | →$7 | 評級下調 | 購買→Hold |
| 07/20/2022 | 541.03% | 奧本海默 | →$20 | 開始承保 | →跑贏大盤 |
| 11/04/2021 | 797.44% | HC Wainwright公司 | $27→$28 | 維護 | 買 |
| 07/21/2021 | 765.38% | HC Wainwright公司 | $34→$27 | 維護 | 買 |
| 03/11/2021 | 669.23% | Stifel | $4→$24 | 升級 | 持有→購買 |
| 12/03/2020 | 925.64% | 康託·菲茨傑拉德 | →$32 | 開始承保 | →超重 |
| 11/23/2020 | 989.74% | HC Wainwright公司 | $33→$34 | 維護 | 買 |
| 2020/08/26 | 733.33% | 派珀·桑德勒 | →$26 | 開始承保 | →超重 |
| 08/04/2020 | 957.69% | HC Wainwright公司 | →$33 | 開始承保 | →購買 |
| 04/16/2020 | 284.62% | 傑富瑞 | →$12 | 開始承保 | →購買 |
What is the target price for Lumos Pharma (LUMO)?
Lumos Pharma(LUMO)的目標價是多少？
The latest price target for Lumos Pharma (NASDAQ: LUMO) was reported by HC Wainwright & Co. on September 6, 2023. The analyst firm set a price target for $28.00 expecting LUMO to rise to within 12 months (a possible 797.44% upside). 11 analyst firms have reported ratings in the last year.
魯莫斯製藥公司(納斯達克代碼：LUMO)的最新目標價是由HC Wainwright&Co.於2023年9月6日報道的。這家分析公司將目標價定為28美元，預計LUMO將在12個月內上漲(可能上漲797.44%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Lumos Pharma (LUMO)?
盧莫斯製藥公司(Lumos Pharma)的最新分析師評級是多少？
The latest analyst rating for Lumos Pharma (NASDAQ: LUMO) was provided by HC Wainwright & Co., and Lumos Pharma reiterated their buy rating.
分析師對Lumos Pharma(納斯達克代碼：LUMO)的最新評級由HC Wainwright&Co.提供，Lumos Pharma重申其買入評級。
When is the next analyst rating going to be posted or updated for Lumos Pharma (LUMO)?
Lumos Pharma(LUMO)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lumos Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lumos Pharma was filed on September 6, 2023 so you should expect the next rating to be made available sometime around September 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公開財務報表，與Lumos Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Lumos Pharma的上一次評級是在2023年9月6日提交的，所以你應該預計下一次評級將在2024年9月6日左右的某個時候公佈。
Is the Analyst Rating Lumos Pharma (LUMO) correct?
分析師對Lumos Pharma的評級正確嗎？
While ratings are subjective and will change, the latest Lumos Pharma (LUMO) rating was a reiterated with a price target of $0.00 to $28.00. The current price Lumos Pharma (LUMO) is trading at is $3.12, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Lumos Pharma(LUMO)評級被重申，目標價在0.00美元至28.00美元之間。Lumos Pharma目前的交易價格為3.12美元，在分析師的預測範圍內。